Table 4.

Monoclonal antibody therapy in AD.

Monoclonal	Target	Animal Model	Clinical Trial	Effect(s)	References
Bapineuzumab	β-amyloid	Yes	Yes	None	[328-329]
AAB-003 (modified Bapineuzumab)	β-amyloid	Yes	Yes	None	[330]
Solanezumab, Ganteberumab	β-amyloid	Yes	Yes	None	[331-334]
Crenezumab	β-amyloid	Yes	Yes	None	[335]
PBD-C06	pGlu-Aβ	Yes	No	Unknown (in humans)	[336]
Donanemab	β-amyloid	Yes	Yes (early AD) NCT03367403 NCT02624778	Cognitive improvement	[337-339]
Aducanumab	β-amyloid aggregates	Yes	Yes (FDA approved) NCT02484547 NCT02477800 Other trials are active	Cognitive improvement	[340-344]
Lecanemab	β-amyloid aggregates	Yes	Yes (FDA approved) NCT01230853 Other trials are active	Improvement of clinical symptoms. Secondary effects?	[345-347]